Aqemia
Designs small-molecule drug candidates with physics-based calculations feeding a generative model, for its own pipeline and for pharma partners such as Sanofi.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2024-12-10Round (unnamed)Round
$38M
For: prepare clinical trials, open a London office
Toward the clinicCommercial roll-out
Company counsel's notice; it says the round brings total funds raised past $100M. Stage not named.
Lead · Cathay Innovation ✓WendelBpifrance Large Venture ✓Eurazeo ✓Elaia ✓
The investor's own page says · Cathay Innovation: Series A 2024; own post 2024-12-10
- 2024-01-30Series A extensionRound
€30M≈ $32.5M
For: grow its wholly owned pipeline and platform
Models and platform
A second €30M that brings the Series A to €60M in total.
Lead · Wendel GrowthBpifrance Large Venture ✓Eurazeo ✓Elaia ✓
On the deal: Victoire Laurenty (Investment Director, Wendel Growth)
- 2022-10-19Series ARound
€30M≈ $29.3M
For: scale the platform and its own pipeline, oncology first
Models and platform
Co-lead · Eurazeo ✓Co-lead · Bpifrance Large Venture ✓Elaia ✓
On the deal: Antoine Zins (Investment Director, Eurazeo); Laurent Higueret (Senior Investment Director, Bpifrance Large Venture)
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
On the investors' own sites
Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.
- Bpifrance Large Venturebpifrance.com ↗
- Cathay InnovationSeries A 2024; own post 2024-12-10cathayinnovation.com ↗
- Elaiaelaia.com ↗
- EurazeoInvestment date 06/2021eurazeo.com ↗
Its investors also backed
Other companies on this page whose rounds name the same investor.